Latest Regulatory Clearance News

Shift4 Payments, LLC has entered into a definitive scheme implementation agreement to acquire Smartpay Holdings Limited at NZ$1.20 per share, subject to regulatory and shareholder approvals. The transaction outlines a detailed timetable and conditions, including Overseas Investment Office consent and court sanction.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.

Alligator Energy advances regulatory approvals and construction preparations for its Samphire Uranium Project’s Field Recovery Trial, a critical step toward commercial production.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Santos Limited has received a compelling non-binding proposal from the XRG Consortium to acquire the company at a significant premium, prompting the board to engage in due diligence and negotiations. This move could reshape the Australian energy landscape if finalized.

ASPI Isotopes Inc. has proposed a scheme to acquire all Renergen shares at a 41.3% premium, aiming to create a global critical materials powerhouse. The deal, subject to shareholder and regulatory approval, will delist Renergen from multiple exchanges.

Aguia Resources is ramping up production at its high-grade Santa Barbara gold project in Colombia while advancing a low-capital phosphate operation in Brazil, setting the stage for robust cash flow generation.

Cleo Diagnostics unveils a pioneering blood test for early ovarian cancer detection, boasting superior accuracy to existing methods and targeting a significant U.S. market opportunity.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

Marvel Gold Limited has signed a binding agreement to sell its Mali gold assets to Anchises Capital for AUD 1.65 million, marking a strategic shift towards new growth opportunities in Tanzania.

Mayne Pharma disputes Cosette Pharmaceuticals’ attempt to terminate their acquisition agreement, with a key court hearing postponed to September and a crucial shareholder vote set for June 18.

PainChek has advanced its US regulatory approval process with a positive FDA meeting, setting the stage for a potential market debut of its pain assessment app in late 2025.